Format

Send to

Choose Destination
Ecancermedicalscience. 2008;2:118. doi: 10.3332/ecancer.2008.118. Epub 2008 Dec 8.

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.

Author information

1
Division of Hematology, Mount Sinai School of Medicine, New York, NY, USA. lewis.silverman@mssm.edu

Abstract

The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood110 817). The current treatment paradigm, which is based on a relationship between complete remission (CR) and survival, is increasingly being questioned (Cheson (2006) Blood108 419). Results of AZA-001 show CR is sufficient but not necessary to prolong OS (List (2008) Clin Oncol26 7006). Indeed, the AZA CR rate in AZA-001 was modest (17%), while partial remission (PR, 12%) and haematological improvement (HI, 49%) were also predictive of prolonged survival. This analysis was conducted to assess the median number of AZA treatment cycles associated with achievement of first response, as measured by IWG 2000-defined CR, PR or HI (major + minor). The number of treatment cycles from first response to best response was also measured.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center